Rituximab: A promising therapy in systemic lupus erythematosus
- 31 January 2006
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 5 (1), 18-24
- https://doi.org/10.1016/j.autrev.2005.05.006
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trialArthritis & Rheumatism, 2005
- Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusArthritis & Rheumatism, 2004
- T cells in the pathogenesis of systemic lupus erythematosusClinical Immunology, 2004
- The central role of dendritic cells and interferon-α in SLECurrent Opinion in Rheumatology, 2003
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosusBritish Journal of Haematology, 2002
- Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivityNature Immunology, 2001